Filtered By:
Condition: Heart Attack
Therapy: Thrombolytic Therapy

This page shows you your search results in order of relevance. This is page number 4.

Order by Relevance | Date

Total 48 results found since Jan 2013.

Bacterial staphylokinase as a promising third-generation drug in the treatment for vascular occlusion.
Abstract Vascular occlusion is one of the major causes of mortality and morbidity. Blood vessel blockage can lead to thrombotic complications such as myocardial infarction, stroke, deep venous thrombosis, peripheral occlusive disease, and pulmonary embolism. Thrombolytic therapy currently aims to rectify this through the administration of recombinant tissue plasminogen activator. Research is underway to design an ideal thrombolytic drug with the lowest risk. Despite the potent clot lysis achievable using approved thrombolytic drugs such as alteplase, reteplase, streptokinase, tenecteplase, and some other fibrinoly...
Source: Molecular Biology Reports - October 31, 2019 Category: Molecular Biology Authors: Nedaeinia R, Faraji H, Javanmard SH, Ferns GA, Ghayour-Mobarhan M, Goli M, Mashkani B, Nedaeinia M, Haghighi MHH, Ranjbar M Tags: Mol Biol Rep Source Type: research

Surgical Treatment of Pulmonary Embolism and Chronic Thromboembolic Pulmonary Hypertension
Curr Pharm Des. 2021 Sep 2. doi: 10.2174/1381612827666210902152539. Online ahead of print.ABSTRACTVenous thromboembolism clinically presents as deep venous thrombosis or acute pulmonary embolism and is globally recognized as the third most frequent acute cardiovascular syndrome after myocardial infarction and stroke. Although pulmonary embolism does not typically cause severe pulmonary hypertension in the acute setting, thrombus organization and fibrosis can lead to stenosis or obliteration of pulmonary arteries in a minority of patients, which in turn result in severe pulmonary hypertension and right heart failure. This d...
Source: Current Pharmaceutical Design - September 3, 2021 Category: Drugs & Pharmacology Authors: Nikolaos Papakonstantinou Polydoros Kampaktsis Filippos-Paschalis Rorris Ilias Doulamis Aspasia Tzani Sotirios Katsaridis Dimitrios Avgerinos Source Type: research

In-hospital gastrointestinal bleeding in patients with acute myocardial infarction: incidence, outcomes and risk factors analysis from China Acute Myocardial Infarction Registry
Conclusions GIB is associated with both in-hospital and follow-up MACCEs. Gastrointestinal prophylactic treatment should be administered to patients with AMI who receive primary PCI, thrombolytic therapy or GPIIb/IIIa receptor inhibitor. Trial registration number NCT01874691.
Source: BMJ Open - September 7, 2021 Category: General Medicine Authors: Shi, W., Fan, X., Yang, J., Ni, L., Su, S., Yu, M., Yang, H., Yu, M., Yang, Y., On behalf of China Acute Myocardial Infarction(CAMI) Registry Study Group Tags: Open access, Cardiovascular medicine Source Type: research